TherapeuticsMD (NASDAQ:TXMD) Posts Earnings Results, Beats Estimates By $6.16 EPS

TherapeuticsMD (NASDAQ:TXMD) issued its earnings results on Friday. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of ($6.12) by $6.16, FiscalAI reports. The business had revenue of $1.26 million for the quarter, compared to analyst estimates of $19.77 million. TherapeuticsMD had a negative net margin of 6.64% and a negative return on equity of 1.09%.

TherapeuticsMD Trading Up 2.7%

NASDAQ TXMD traded up $0.05 during trading hours on Friday, reaching $1.87. 50,464 shares of the company’s stock were exchanged, compared to its average volume of 42,193. The stock has a market cap of $21.64 million, a PE ratio of 93.50 and a beta of 0.68. TherapeuticsMD has a one year low of $1.43 and a one year high of $2.95. The firm has a fifty day moving average of $1.98 and a 200-day moving average of $2.09.

Wall Street Analyst Weigh In

Separately, Weiss Ratings lowered shares of TherapeuticsMD from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, November 4th. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the stock currently has an average rating of “Sell”.

About TherapeuticsMD

TherapeuticsMD, Inc. was a pharmaceutical company focused on developing and commercializing products for women’s health. Its portfolio addressed contraception, menopause-related conditions, pregnancy-related nausea, and nutritional support, with products marketed primarily in the United States. The company’s principal products included ANNOVERA, a reusable, year-long vaginal contraceptive system; IMVEXXY, vaginal inserts containing estradiol for the treatment of moderate to severe vaginal symptoms associated with menopause; and BIJUVA, an oral hormone therapy combining estradiol and progesterone.